Details for New Drug Application (NDA): 210054
✉ Email this page to a colleague
NDA 210054 describes RANOLAZINE, which is a drug marketed by Accord Hlthcare, Actavis Elizabeth, Ajanta Pharma Ltd, Alkem Labs Ltd, Allied, Amneal, Ani Pharms, Aurobindo Pharma, Cadila, Chartwell Rx, Cipla, Glenmark Pharms Ltd, Hetero Labs Ltd Iii, Mankind Pharma, Micro Labs, Novast Labs, Piramal, Praxgen, Rising, Sciegen Pharms Inc, Sun Pharm, Sunshine, Unichem, and Vkt Pharma, and is included in twenty-four NDAs. It is available from twenty-seven suppliers. Additional details are available on the RANOLAZINE profile page.
The generic ingredient in RANOLAZINE is ranolazine. There are twenty-three drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ranolazine profile page.
The generic ingredient in RANOLAZINE is ranolazine. There are twenty-three drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ranolazine profile page.
Summary for 210054
| Tradename: | RANOLAZINE |
| Applicant: | Ajanta Pharma Ltd |
| Ingredient: | ranolazine |
| Patents: | 0 |
Suppliers and Packaging for NDA: 210054
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| RANOLAZINE | ranolazine | TABLET, EXTENDED RELEASE;ORAL | 210054 | ANDA | Ajanta Pharma USA Inc. | 27241-125 | 27241-125-02 | 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-125-02) |
| RANOLAZINE | ranolazine | TABLET, EXTENDED RELEASE;ORAL | 210054 | ANDA | Ajanta Pharma USA Inc. | 27241-125 | 27241-125-05 | 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-125-05) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 500MG | ||||
| Approval Date: | May 28, 2019 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 1GM | ||||
| Approval Date: | May 28, 2019 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
